obesity research comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-26. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
=== Diagnosis === The assessment of vitamin B6 status is essential, as the clinical signs and symptoms in less severe cases are not specific. The three biochemical tests most widely used are plasma PLP concentrations, the activation coefficient for the erythrocyte enzyme aspartate aminotransferase, and the urinary excretion of vitamin B6 degradation products, specifically urinary PA. Of these, plasma PLP is probably the best single measure, because it reflects tissue stores. Plasma PLP of less than 10 nmol/L is indicative of vitamin B6 deficiency. A PLP concentration greater than 20 nmol/L has been chosen as a level of adequacy for establishing Estimated Average Requirements and Recommended Daily Allowances in the USA. Urinary PA is also an indicator of vitamin B6 deficiency; levels of less than 3.0 mmol/day is suggestive of vitamin B6 deficiency. Other methods of measurement, including UV spectrometric, spectrofluorimetric, mass spectrometric, thin-layer and high-performance liquid chromatographic, electrophoretic, electrochemical, and enzymatic, have been developed. The classic clinical symptoms for vitamin B6 deficiency are rare, even in developing countries. A handful of cases were seen between 1952 and 1953, particularly in the United States, having occurred in a small percentage of infants who were fed a formula lacking in pyridoxine.
=== Oath of neutrality === On 15 March 1900, Lord Roberts proclaimed an amnesty for all burghers, except leaders, who took an oath of neutrality and returned quietly to their homes. It is estimated that between 12,000 and 14,000 burghers took this oath between March and June 1900.
=== Flexible linkers === Disordered regions are often found as flexible linkers or loops connecting domains. Linker sequences vary greatly in length but are typically rich in polar uncharged amino acids. Flexible linkers allow the connecting domains to freely twist and rotate to recruit their binding partners via protein domain dynamics. They also allow their binding partners to induce larger scale conformational changes by long-range allostery. The flexible linker of FBP25 which connects two domains of FKBP25 is important for the binding of FKBP25 with DNA.
After two years, the inquiry concluded with three principal findings and several recommendations, including required training for administrators, directors of nursing, and service organizations, improved screening processes and background checks for new hires, minimizing the use of agency nurses in long-term care homes, improved reporting processes for critical incidents, and changes to certain Ontario provincial regulations.
When Aristotle says that the body is matter for a living thing, he may be using the word "body" to refer to the matter that makes up the fully organized body, rather than the fully organized body itself. Unlike the fully organized body, this "body" remains the same thing even after death. In contrast, when he says that the body is no longer the same after its death, he is using the word "body" to refer to the fully organized body.
Sources: en.wikipedia.org
2-Hydroxybutyric acid, is a hydroxybutyric acid with the hydroxyl group on the carbon adjacent to the carboxyl. It is a chiral compound having two enantiomers, D-2-hydroxybutyric acid and L-2-hydroxybutyric acid. Its conjugate base is known as alpha-hydroxybutyrate and α-hydroxybutyrate.
An additional major contributor to chemotherapy resistance is inter and intra patient response variability. Inter, referring to differences between patients, and intra referring to differences within an individual patient. The oncology community recognizes inter-patient response variability as a wide-scale phenomenon of pressing concern as variability is even observed in tumors before exposure to targeted treatment. Inter and intra patient response variability further exacerbates the difficulties in ensuring long-term effectiveness of treatment where tumor growth does not progress and shrinkage is permanent. There are many factors at the cellular and genomic level that contribute to variability between patients and within the individual. In a more narrow scope of events, tumor heterogeneity and cellular heterogeneity are the two overarching contributors to this issue. Tumor heterogeneity refers to the diversity of cells within the same tumor microenvironment. Regional and environmental differences within a tumor actively shape its heterogeneity and promote the growth and survival of tumor cells. Variation in oxygen availability, acidity, and growth factors in different regions of the tumor place different selective pressures in each region of the environment, leading to tumor cells with varying sensitivity within the same microenvironment. Additionally, distance from vascular beds in the tumor microenvironment creates an uneven distribution of the targeted drug to all cells in the tumor, failing to effectively kill all of the tumor cells.
Analyte ions are formed at ambient pressure during Penning and chemical ionization. The mass spectrometry analysis, however, takes place at high vacuum condition. Therefore, ions entering the mass spectrometer, first go through a source - to - analyzer interface (vacuum interface), which was designed in order to bridge the atmospheric pressure region to the mass spectrometer vacuum. It also minimizes spectrometer contamination. In the original JEOL atmospheric pressure interface used for DART, ions are directed to the ion guide through (outer) і and (inner) іі skimmer orifices by applying a slight potential difference between them: orifice і : 20 V and orifice іі : 5 V. The alignment of the two orifices is staggered to trap neutral contamination and protect the high-vacuum region. Charged species (ions) are guided to the second orifice through an intermediate cylindrical electrode ("ring lens"), but neutral molecules travel in a straight pathway and are thus blocked from entering the ion guide. The neutral contamination is then removed by the pump. The DART source can be operated in surface desorption mode or transmission mode. In the ordinary surface desorption mode, the sample is positioned in a way, which enables the reactive DART reagent ion stream to flow on to the surface while allowing the flow of desorbed analyte ions into interface. Therefore, this mode requires that the gas stream grazes the sample surface and does not block gas flow to the mass spectrometer sampling orifice.
Guming Holdings Limited (known under the brand name Good me; Chinese: 古茗; pinyin: Gǔmíng; lit. 'Ancient tea water') is a publicly listed Chinese teahouse chain. Founded in 2010 by Wang Yun'an and headquartered in Hangzhou, Zhejiang, the company operates primarily in China's lower-tier cities, selling beverages such as fruit tea, milk tea, and coffee through a franchise model. As of late 2024, Good me had expanded to nearly 9,800 outlets nationwide, making it one of China's largest bubble tea chains. Guming Holdings went public on the Hong Kong Stock Exchange in February 2025, raising approximately US$233 million in its initial public offering (IPO).
Sources: en.wikipedia.org
The witch doctor drinks a very small amount each time and knows well how many times he can sample the brew without losing his senses to properly conduct the ritual and lead the choir". Another report produced in 1737 by the missionary Pablo Maroni, describes the use of a psychoactive liana called ayahuasca for divination in the Napo River, Ecuador: "For divination, they use a beverage, some of white datura flowers, which they also call Campana due to its shape, and others from a vine commonly known as Ayahuasca, both highly effective at numbing the senses and even at taking one's life if taken in excess. They also occasionally use these substances for the treatment of common illnesses, especially headaches. So, the person who wants to divine drinks the chosen substance with certain rituals, and while deprived of their senses from the mouth downwards, to prevent the strength of the plant from harming them, they remain in this state for many hours and sometimes even two or three days until the effects run their course, and the intoxication subsides. After this, they reflect on what their imagination revealed, which occasionally remains with them for delirium. This is what they consider accomplished and propagate as an oracle." Latter reports were produced by Juan Magnin in 1740, describing ayahuasca use as a medicinal plant by the "Jivaroan" peoples (called ayahuessa) and by Franz Xaver Veigl in 1768, that reports about several "dangerous plants", including a bitter liana used for precognition and sorcery.
=== Positive selection === T cells have distinct receptors. These receptors are formed by the process of V(D)J recombination gene rearrangement stimulated by RAG1 and RAG2 genes. This process is error-prone, and some thymocytes do not make functional T-cell receptors, whereas other thymocytes make autoreactive T-cell receptors. If a functional T cell receptor is formed, the thymocyte expresses the cell surface proteins CD4 and CD8 simultaneously. The survival and nature of the T cell then depend on its interaction with surrounding thymic epithelial cells. The T cell receptor interacts with the MHC molecules on the surface of epithelial cells. A T cell with a receptor that doesn't react, or reacts weakly, dies by apoptosis. T cells that react survive and proliferate. A mature T cell expresses either CD4 or CD8, but not both. This depends on the binding strength between the TCR and MHC class 1 or class 2. A T cell receptor that binds mostly to MHC class I tends to produce a mature "cytotoxic" CD8 positive T cells those that bind mostly to MHC class II typically produce a CD4 positive T cell.
== Medicinal properties == Mashua has putative anaphrodisiac effects. It has been recorded by the Spanish chronicler Cobo that mashua was fed to their armies by the Inca Emperors, "that they should forget their wives". Studies of male rats fed on mashua tubers have shown a 45% drop in testosterone levels due to the presence of isothiocyanates. Mashua contains docosatetraenoylethanolamide, a cannabinoid structurally similar to anandamide that also acts on the cannabinoid (CB1) receptor among other structurally related compounds such as N–oleoyldopamine. Topical mashua in a 1% gel formulation has proven to increase the healing activities of open wounds in mice populations. Further studies are necessary to determine potential wound healing success for human application.
==== Transplastomic plants ==== Recently, chloroplasts have caught attention by developers of genetically modified crops. Since, in most flowering plants, chloroplasts are not inherited from the male parent, transgenes in these plastids cannot be disseminated by pollen. This makes plastid transformation a valuable tool for the creation and cultivation of genetically modified plants that are biologically contained, thus posing significantly lower environmental risks. This biological containment strategy is therefore suitable for establishing the coexistence of conventional and organic agriculture. While the reliability of this mechanism has not yet been studied for all relevant crop species, recent results in tobacco plants are promising, showing a failed containment rate of transplastomic plants at 3 in 1,000,000.
== Biography == Theodoros Angelopoulos was born in Athens on 27 April 1935. His father Spyros hailed from the town of Ampeliona, Messenia in the Peloponnese. During the Greek Civil War, his father was taken hostage and returned when Angelopoulos was 9 years old; according to the director, the absence of his father and looking for him among the dead bodies (during the "Dekemvriana" in Athens) had a great impact on his cinematography. He studied law at the University of Athens, but after his military service went to Paris to attend the Sorbonne. He soon dropped out to study film at the Institut des hautes études cinématographiques (IDHEC) before returning to Greece. There, he worked as a journalist and film critic. Angelopoulos began making films after the 1967 coup that began the Regime of the Colonels. He made his first short film in 1968 and in the 1970s he began making a series of political feature films about modern Greece: Days of '36 (Meres Tou 36, 1972), The Travelling Players (O Thiassos, 1975) and The Hunters (I Kynighoi, 1977). In 1978, he was a member of the jury at the 28th Berlin International Film Festival.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.